SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are associated with increased risk for diabetic ketoacidosis.3,4,8–10 Clinical trials and observational studies suggest a class effect, but the previous analyses have been limited by small numbers of events and whether there is difference in risk for diabetic ketoacidosis between empagliflozin and dapagliflozin is uncertain.